Prospects for a hepcidin mimic to treat β-thalassemia and hemochromatosis

Expert Review of Hematology

Volumn 4, Issue 3, 2011, Pages 233-235

  Parrow, Nermi L ^a   Gardenghi, Sara ^a   Rivella, Stefano ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

thalassemia; anemia; hemochromatosis; hepcidin; ineffective erythropoiesis; iron overload; splenomegaly

Indexed keywords

FERROPORTIN; HEPCIDIN; HEPCIDIN AGONIST; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AGONIST; BETA THALASSEMIA; DRUG ACTIVITY; GENE EXPRESSION; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-THALASSEMIA; CATION TRANSPORT PROTEINS; DISEASE MODELS, ANIMAL; HEMOCHROMATOSIS; IRON; MICE; MICE, KNOCKOUT; REACTIVE OXYGEN SPECIES;

EID: 79959262524     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.22     Document Type: Review

References (20)

1. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62, 347-360 (2011)
2. Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38(5), 531-539 (2006)
3. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 108(9), 3204-3209 (2006)
4. Chung B, Verdier F, Matak P, Deschemin JC, Maueux P, Vaulont S. Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J. 24(6), 2093-2103 (2010)
5. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108(12), 3730-3735 (2006)
6. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13(9), 1096-1101 (2007)
7. Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv. Hematol. 2010, 358283 (2010)
8. Tanno T, Porayette P, Sripichai O et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114(1), 181-186 (2009)
9. Gardenghi S, Ramos P, Marongiu MF et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J. Clin. Invest. 120(12), 4466-4477 (2010)
10. CavazzanαCalvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human βthalassaemia. Nature 467(7313), 318-322 (2010)
11. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139(2), 393-408 (2010)
12. De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due to mutations in ferroportin. Haematologica 91(1), 92-95 (2006)
13. Li H, Rybicki AC, Suzuka SM et al. Transferrin therapy ameliorates disease in b-thalassemic mice. Nat. Med. 16(2), 177-182 (2010)
14. Moran-Jimenez MJ, Mendez M, Santiago B et al. Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur. J. Clin. Invest. 40(6), 511-517 (2010)
15. Viatte L, Nicolas G, Lou DQ et al. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood 107(7), 2952-2958 (2006)
16. Nicolas G, Viatte L, Lou DQ et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat. Genet. 34(1), 97-101 (2003)
17. Corradini E, Schmidt PJ, Meynard D et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology 139(5), 1721-1729 (2010)
18. Roy CN. Anemia of inflammation. Hematology Am. Soc. Hematol. Educ. Program. 2010, 276-280 (2010)
19. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J. Hepatol. 54(1), 173-181 (2011)
20. Maes K, Nemeth E, Roodman GD et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116(18), 3635-3644 (2010).